Suchergebnisse - "Gasink, Christopher"

PubPharm (33)

1

Safety of Ustekinumab in Inflammatory Bowel Disease : Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis

enthalten in: Journal of Crohn's & colitis | 2024

von Ghosh, S. | Feagan, B. | Ott, E. | +10

2

Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Colombel, J. | Sands, B. | Gasink, C. | +10

ErratumIn: Clin Gastroenterol Hepatol. 2024 Apr 3;:. - PMID 38582496

3

HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients

enthalten in: Inflammatory bowel diseases | 2023

von Colombel, J. | Martín-Arranz, M. | Brinkman, B. | +3

CommentIn: Inflamm Bowel Dis. 2024 Apr 06;:. - PMID 38581670

4

Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

enthalten in: Clinical therapeutics | 2022

von Adedokun, O. | Xu, Z. | Gasink, C. | +3

5

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials : Pregnancy Outcomes Through Up To 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis

enthalten in: Crohn's & colitis 360 | 2022

von Abraham, B. | Ott, E. | Busse, C. | +5

6

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease : a multicentre, randomised, double-blind, parallel-group, phase 3b trial

enthalten in: Lancet (London, England) | 2022

von Sands, B. | Irving, P. | Hoops, T. | +117

CommentIn: Lancet. 2022 Jun 11;399(10342):2169-2171. - PMID 35691307

7

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease : The IM-UNITI Trial

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Sandborn, W. | Rebuck, R. | Wang, Y. | +11

8

Safety of Ustekinumab in Inflammatory Bowel Disease : Pooled Safety Analysis of Results from Phase 2/3 Studies

enthalten in: Inflammatory bowel diseases | 2021

von Sandborn, W. | Feagan, B. | Danese, S. | +10

ErratumIn: Inflamm Bowel Dis. 2021 Jun 15;27(7):1175. - PMID 33511983

9

IM-UNITI : Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease

enthalten in: Journal of Crohn's & colitis | 2020

von Hanauer, S. | Sandborn, W. | Feagan, B. | +10

CommentIn: J Crohns Colitis. 2020 Jan 1;14(1):1-3. - PMID 31605526

10

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease

enthalten in: Gastroenterology | 2019

von Li, K. | Friedman, J. | Chan, D. | +9